Organization (Industry)
ACLARIS THERAPEUTICS, INC.
ClinicalTrials.gov lists ACLARIS THERAPEUTICS, INC. as lead sponsor of 33 trials. It has 19 active development programs and 4 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers ACLARIS THERAPEUTICS, INC.: 33 lead-sponsored trials and 3 legal-entity registrations.
Disease areas (19)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Keratosis, Seborrheic | 8 |
| Papillomavirus Infections | 6 |
| Warts | 6 |
| Alopecia | 5 |
| Dermatitis, Atopic | 5 |
Showing 5 of 19 disease areas.
Trials by start year as sponsor or collaborator (13)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 3 |
| 2024 | 1 |
| 2023 | 1 |
| 2022 | 3 |
| 2021 | 1 |
| 2020 | 3 |
| 2019 | 2 |
| 2018 | 8 |
| 2017 | 7 |
| 2016 | 3 |
Showing 10 of 13 years.
Recruitment duration, a model prediction: none of the 33 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (19)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| ATI-045 | Eczema | Phase 2 | 1 |
| ATI-045 | Dermatitis, Atopic | Phase 2 | 1 |
| METHOTREXATE | Arthritis, Rheumatoid | Phase 2 | 2 |
| ATI-450 20 mg oral tablet BID | Arthritis, Rheumatoid | Phase 2 | 1 |
| ATI-1777 2.0% w/w | Dermatitis, Atopic | Phase 2 | 1 |
Showing 5 of 19 active programs.
Approved assets (4)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| A-101 (32.5) Topical Solution | 4 |
| Oxymetazoline HCL 1.0% Cream | 1 |
| Hydrogen Peroxide | 4 |
| METHOTREXATE | 2 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 62% hit target (n=26) | 21% on time (n=24) |
Journals published in (2)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| JID innovations : skin science from molecules to population health | 1 |
| Journal of drugs in dermatology : JDD | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 20 | 9 | 2025-09-02 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 7,826,000 | -64,923,000 | 52,645,000 |
| 2024 | 18,720,000 | -132,065,000 | 33,586,000 |
| 2023 | 31,249,000 | -88,481,000 | 98,384,000 |
| 2022 | 29,752,000 | -86,908,000 | 77,813,000 |
| 2021 | 6,761,000 | -90,865,000 | 43,813,000 |
| 2020 | 6,482,000 | -51,015,000 | 29,338,000 |
| 2019 | 4,227,000 | -161,354,000 | 64,165,000 |
| 2018 | 6,151,000 | -132,738,000 | 60,841,000 |
| 2017 | 1,683,000 | -68,523,000 | 35,804,000 |
| 2016 | not reported | -48,079,000 | 33,476,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (30)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-03-10 | ATM offering | 20,000,000 | Sec extracted |
| 2026-03-09 | ATM offering | 39,800,000 | Sec extracted |
| 2025-02-27 | Other financing | not disclosed | Edgar offerings |
| 2024-12-31 | Other financing | not disclosed | Edgar offerings |
| 2024-11-19 | Private placement | 79,999,999 | Form d |
Showing 5 of 30 events.
FDA untitled letters (1)
| Issue date | Letter |
|---|---|
| 2019-06-14 | 128151 |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (2)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Washington University in St. Louis | Co sponsors trial with | 1 |
| Government of the United States of America | Co sponsors trial with | 1 |
Latest dated events (87)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-03-10 | At-the-market offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-03-09 | At-the-market offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-09-02 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-08-12 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-07-29 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 87 events.
Biomarker capability evidence (71)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CDK4 | Trial collaborator | Named in trial inclusion criteria |
| CRP | Trial sponsor | Named in trial inclusion criteria |
| ERBB2 | Trial collaborator | Named in trial inclusion criteria |
| NLRP3 | Trial sponsor | Named in trial inclusion criteria |
| AGA | Trial sponsor | Named in trial exclusion criteria |
Showing 5 of 71 evidence rows.
On Scientist.com
ACLARIS THERAPEUTICS, INC. is listed as a research supplier in the Scientist.com network.
Service areas
Aclaris focuses on identifying, developing, and commercializing novel topical dermatological therapeutics that serve the largest and fastest growing sectors of the dermatology market and that fill unmet medical and aesthetic needs. The Company expects to develop its lead product, A-101, as a medical-professional administered in-office topical therapy for the treatment of seborrheic keratosis. Additionally the Company is pursuing indications which include the treatment of a number of other dermatologic conditions. Our team is also currently evaluating other equally promising dermatologic...
Show the full description
Aclaris focuses on identifying, developing, and commercializing novel topical dermatological therapeutics that serve the largest and fastest growing sectors of the dermatology market and that fill unmet medical and aesthetic needs. The Company expects to develop its lead product, A-101, as a medical-professional administered in-office topical therapy for the treatment of seborrheic keratosis. Additionally the Company is pursuing indications which include the treatment of a number of other dermatologic conditions. Our team is also currently evaluating other equally promising dermatologic assets that are in various stages of preclinical & clinical development.
- Website
- www.aclaristx.com
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, fda warning letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Aclaris on Scientist.com
For prices, more details, or to contact Aclaris, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.